| Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain S Díaz-Cerezo, ÁM García-Aparicio, J Parrondo, LA Vallejo-Aparicio Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad …, 2015 | 10 | 2015 |
| Economic evaluation of Thrombopoietin Receptor Agonists in the treatment of chronic primary immune thrombocytopenia J Parrondo, C Grande, J Ibáñez, J Palau, JA Páramo, G Villa Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad …, 2013 | 10 | 2013 |
| Cost-effectiveness analysis of belimumab in the treatment of adult systemic lupus erythematosus (Sle) Patients With Positive Biomarkers In Spain LA Vallejo-Aparicio, S Díaz-Cerezo, J Parrondo, AM García-Aparicio Value in Health 17 (7), A530, 2014 | 6 | 2014 |
| Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART J Berenguer, J Parrondo, RJ Landovitz Plos one 14 (7), e0219802, 2019 | 5 | 2019 |
| Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: A mathematical model J Berenguer, J Parrondo, RJ Landovitz PloS one 15 (7), e0236032, 2020 | 3 | 2020 |
| Monte-Carlo simulation to estimate the health care costs avoided with fluticasone furoate/vilanterol due to exacerbation rate reduction in spanish COPD patients S Mayoralas, A Huerta, J Parrondo, C Rubio-Terrés, D Rubio-Rodríguez Value in Health 17 (7), A603, 2014 | 3 | 2014 |
| Evaluación económica del tratamiento de la trombocitopenia inmune primaria crónica refractaria con agonistas del receptor de la trombopoyetina J Parrondo, C Grande, J Ibáñez, J Palau, JA Páramo, G Villa Farmacia Hospitalaria 37 (3), 182-191, 2013 | 3 | 2013 |
| Costes sanitarios evitados con furoato de fluticasona/vilanterol debido a la reducción de la tasa de exacerbaciones en pacientes con enfermedad pulmonar obstructiva crónica SM Alises, A Huerta, J Parrondo PharmacoEconomics Spanish Research Articles 3 (13), 97-104, 2016 | 2 | 2016 |
| Costes sanitarios evitados con furoato de fluticasona/vilanterol debido a la reducción de la tasa de exacerbaciones en pacientes con enfermedad pulmonar obstructiva crónica S Mayoralas Alises, A Huerta, J Parrondo PharmacoEconomics Spanish Research Articles 13, 97-104, 2016 | 1 | 2016 |
| Cost-utility analysis of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) as a single tablet treatment of naive HIV infected patientss J Parrondo, S Moreno, JE Losa, J Berenguer, JM Martinez-Sesmero, ... Value in Health 18 (7), A588-A589, 2015 | 1 | 2015 |
| Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial JE Martín-Herrero, J Parrondo-García, F Rodríguez-Alcántara Enfermedades Infecciosas y Microbiología Clínica 30 (8), 509-510, 2012 | 1 | 2012 |
| Initiation of antiretroviral therapy with integrase strand-transfer inhibitor-based regimens and reduction of the risk of horizontal transmission of HIV-1 J Berenguer, J Parrondo, RJ Landovitz EClinicalMedicine 17, 2019 | | 2019 |
| Shortened Time to ART Initiation in MSM Reduces Risk of HIV-1 Sexual Transmission J Berenguer, J Parrondo, RJ Landovitz AIDS RESEARCH AND HUMAN RETROVIRUSES 34, 283-283, 2018 | | 2018 |
| Análisis de coste-utilidad de la combinación a dosis fijas de dolutegravir/abacavir/lamivudina como tratamiento inicial de pacientes con VIH+ en España S Moreno Guillén, JE Losa García, J Berenguer Berenguer, ... Farmacia Hospitalaria 41 (5), 601-610, 2017 | | 2017 |
| Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV plus patients in Spain S Moreno Guillen, JE Losa Garcia, J Berenguer Berenguer, ... EDITORIAL GARSI, 2017 | | 2017 |
| HOSPITALARIA RM Verdugo, JSR Ferrández, G Calzado-Gómez, GJ Nazco-Casariego, ... HOSPITALARIA, 2017 | | 2017 |
| Cost-Effectiveness Analysis of Eltrombopag As Support Treatment In Chronic Hcv Infected Patients With Thrombocytopenia To Enable Interferon-Based Regimens J Parrondo, RD Rincón, GM Romero, LR Sola, C Roldán Value in Health 17 (7), A532, 2014 | | 2014 |
| Análisis del coste del tratamiento farmacológico de la trombocitopenia inmune primaria mediante agonistas del receptor de la trombopoyetina en España G Villa, J Parrondo, I Pérez-Escolano PharmacoEconomics Spanish Research Articles 10, 99-106, 2013 | | 2013 |
| Analysis of costs and cost-effectiveness of the preferred treatments by GESIDA/National plan for AIDS for initial antiretroviral therapy in 2012 JE Martín-Herrero, J Parrondo-Garcia, F Rodriguez-Alcantara Enfermedades Infecciosas y Microbiologia Clinica 30 (8), 509-10; author …, 2012 | | 2012 |
| HOSPITALARIA SM Guillén, JEL García, JB Berenguer, JMM Sesmero, SC Gomis, ... | | |
Juan Berenguer BerenguerHospital General Universitario Gregorio MarañónVerified email at salud.madrid.org
